＜Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, Milano, Italy, Sep 20 - 23, 2023＞

1. Oka M, Kurose K, Taniguchi H, Takemoto S, Fukuda Mi, Kinoshita A, Kitazaki T, Fukuda Ma, Masuda T, Hattori N, Shimizu K, Nakata M, Kakimi K, Mukae H, and Oga T.
   Antibodies against tumor-associated antigens are associated with response to immune checkpoint therapy for non-small-cell lung cancer.

＜AACR Special Conference: Tumor Immunology and Immunotherapy, October 21-24: Boston, MA, USA＞

1. Sakaeda K, Kurose K, Fukuda Mi, Sugasaki N, Kinoshita A, Kitazaki T, Fukuda Ma, Masuda T, Hattori N, Sakai Y, Irino Y, Yamaki M, Sato T, Mukae H, Oga T, and Oka M.
   Development of automated immunoassay to detect serum biomarkers predicting response to immune checkpoint inhibitors in NSCLC.

＜IASLC: 2022 World Conference on Lung Cancer (WCLC), August 6-9: Vienna, Austria＞

1. Oka M, Kurose K, Sakaeda K, Fukuda M, Sakai Y, Atarashi Y, Shimizu K, Masuda T, Nakatomi K, Kawase S, Suetsugu T, Mizuno K, Takemoto S, Yamaguchi H, Inoue H, Hattori N, Nakata M, Mukae H, and Oga T.
   Serum NY-ESO-1 and XAGE1 antibodies predict and monitor clinical responses to immune checkpoint therapy for NSCLC.

＜American Association of Cancer Research (AACR) Virtual Annual Meeting II, June 22-24, 2020＞ changed by Covid-19 pandemic.

1. Oka M, Kurose K, Yasogawa N, Yamaoka T, Ohue Y, and Oga T.
   Phase 1 study of XAGE1 peptide vaccine in patients with lung adenocarcinoma.
2. Sakai Y, Abo H, Sakaeda K, Atarashi Y, Ide N, Yamaoka T, Kurose K, Noda K, Sato T, Oga T, and Oka M.
   Development of a fully automated immunoassay system for detection of serum NY-ESO-1 and XAGE1 antibodies as biomarkers predicting the clinical efficacy of anti-PD-1 therapy.

＜AACR (American Association of Cancer Research) Special Conference: Tumor Immunology and Immunotherapy, Boston, MA, USA, Nov 17 - 20, 2019＞

1. Oka M, Kurose K, Ohue Y, Karasaki T, Futami J, Irei I, Masuda T, Fukuda Ma, Kinoshita A, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda Mi, Oga T, and Kakimi K.
   Immunological monitoring markers of clinical responses to anti-PD-1 therapy for non-small-cell lung cancer.

＜Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, Paris, France, Sep 25 - 28, 2019＞

1. Oka M, Kurose K, Ohue Y, Karasaki T, Futami J, Irei I, Masuda T, Fukuda Ma, Kinoshita A, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda Mi, Oga T, and Kakimi K.
   Serial antibody responses to XAGE1 and NY-ESO-1 antigens during anti-PD-1 therapy for non-small-cell lung cancer.

＜ASCO-SITC (American Society of Clinical Oncology - Society for Immunotherapy of Cancer), San Francisco, USA, Feb 28 - Mar 2, 2019＞

1. Oka M, Ohue Y, Kurose K, Karasaki T, Masuda T, Fukuda Ma, Kinoshita A, Shimizu K, Nakata M, Hattori N, Kakimi K, Yamaguchi H, Fukuda Mi.
   Serum NY-ESO-1 and XAGE1 antibodies as predictive biomarkers in anti-PD-1 therapy for non-small-cell lung cancer.

＜Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, USA, Sep 30 - Oct 3, 2018＞

1. Kurose K, Ohue Y, Karasaki T, Futami J, Irei I, Masuda T, Fukuda Ma, Kinoshita A, Matsushita H, Shimizu K, Yamaguchi H, Fukuda Mi, Kakimi K, Oka M.
   Serum antibody against NY-ESO-1 and XAGE1 predicts clinical responses to anti-PD-1 therapy in non-small-cell lung cancer.

＜ASCO-SITC (American Society of Clinical Oncology - Society for Immunotherapy of Cancer), San Francisco, USA, Jan 25-27, 2018＞

1. Oka M, Kurose K, Isobe M, Fukuda M, Ohue Y.
   Clinical significance of humoral immunity against XAGE1 cancer-testis antigen in lung adenocarcinoma.

＜IASLC 18th World Conference on Lung Cancer, Yokohama, Japan, Oct 15-18, 2017＞

1. Ohue Y, Kurose K, Isobe M, Fukuda M, Nakayama E, Oka M. Correlation of Clinical Response and XAGE1 Immunity in Lung Adenocarcinoma.
2. Kurose K, Ohue Y, Isobe M, Suzuki S, Wada H, Ueda R, Nakayama E, Oka M. Reviving Chemotherapy Sensityvity after Anti-CCR4 mAb (Mogamulizumab) Treatment in Lung Cancer Patients.

＜European Respiratory Society International Congress, Milan, Italy, Sep 9-13, 2017＞

1. Katoh S, Ikeda M, Matsumoto N, Shimizu H, Oka M. Possible role of IL-25 in eosinophilic lung inflammation in patients with eosinophilic pneumonia.

＜Third CRI-CIMT-EATI-AACR Second International Cancer Immunotherapy Conference, Mainz, Germany, Sep 6-9, 2017＞

1. Kurose K, Ohue Y, Isobe M, Suzuki S, Wada H, Oka M, Ueda R, Nakayama E. Reviving chemotherapy sensitivity after anti-CCR4 mAb (mogamulizumab) treatment in lung cancer patients.

＜101st Annual Meeting of American Association of Cancer Research (AACR), Washington DC, USA, April 1-5, 2017＞

1. Oka M, Ohue Y, Kurose K, Nishio Y, Isobe M, Nakayama E. Immuno-inhibitory pathway, TIM-3/Galectin-9, in lung adenocarcinoma: clinical and in vitro analysis.
2. Fukuda M, Okumura M, Iwakiri T, Arimori K, Takemoto S, Ikeda T, Honda T, Yamaguchi H, Nakatomi K, Kobayashi K, Matsutani M, Oka M, Ashizawa K, Mukae H. The relationship between the UGT1A1*27 and UGT1A1*7 genetic polymorphisms and irinotecan-related toxicities in patients with lung cancer.

＜CRI-CIMT-EATI-AACR Second International Cancer Immunotherapy Conference, New York, USA, Sep 25-28, 2016＞

1. Ohue Y, Kurose K, Nishio Y, Isobe M, Oka M and Nakayama E. Role of TIM-3/Galectin-9 pathway in lung adenocarcinoma.

＜European Respiratory Society International Congress, London, England, Sep 3-7, 2016＞

1. Kobashi Y, Mouri K, Kato S, Oka M. Clinical analysis of glycopeptidolipid core antigen IgA antibodies for cases in which it is difficult to obtain a definite diagnosis of Mycobacterium avium complex pulmonary disease
2. Kobashi Y, Mouri K, Kato S, Oka M. Clinical evaluation of several biomarkers including IFN-γ for the diagnosis of tuberculosis infection

＜European Academy of Allergy and Clinical Immunology, Vienna, Austria, June 11-15, 2016＞

1. Katoh S, Ikeda M, Shimizu H, Oka M. A possible role of galectin-9 in the lung inflammation and fibrosis of patients with intersititial pneumonia.
2. Ikeda M, Katoh S, Shimizu H, Ohue Y, Hasegawa A, Doi K, Oka M. Galectin-9 enhances the effecf of allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model chronic ashtma.

＜European Respiratory Society Annual Congress, Amsterdam, Netherlands, Sep 26-30, 2015＞

1. Kobashi Y, Mouri K, Kato S, Oka M. Clinical evaluation of glycopeptidolipid core antigen IgA antibodies for serodiagnosis of Mycobacterium avium complex pulmonary disease.
2. Kobashi Y, Mouri K, Kato S, Oka M. Clinical evaluation of diagnostic potential of several biomarkers for immunodiagnosis of tuberculosis infection including IGRAs (QFT and T-SPOT.TB)
3. Katoh S, Ikeda M, Shimizu H, Fukushima K, Oka M. Induction of galectin-9 production by viral infection in the lung.

＜CRI-CIMT-EATI-AACR The Inaugural International Cancer Immunotherapy Conference, New York, USA, Sep 16-19, 2015＞

1. Kurose K, Ohue Y, Wada H, Doi T, Nishikawa H, Oka M, Ueda R. Phase Ⅰa study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients.
2. Ohue Y, Kurose K, Oka M, Nakayama E. Discriminant function for predicting survival of lung adenocarcinoma patients developed by using immune parameters of PD-L1,Gal-9, and XAGE1 expression on tumor cells and T cell infiltration score.

＜16th World Conference on Lung Cancer, Denver, Colorado, USA, Sep 6-10, 2015＞

Fukuda M, Ogawara D, Ueno S, Ohue Y, Gyotoku H, Senju H, Takemoto S, Yamaguchi H, Nakatomi K, Nakamura Y, Honda T, Kobayashi K, Nakamura D, Hayashi H, Oka M, Ashizawa K. Drug Fever After Cancer Chemotherapy Is Most Commonly Observed on Post-Treatment Days 3-4

＜22nd Annual International Cancer Immunotherapy Symposium, New York, USA, Oct 5-8, 2014＞

1. Kurose K, Ohue Y, Eikawa S, Nishio Y, Isobe M, Uenaka A, Oka M, and Nakayama E. Increase of activated Tregs in TIL in lung cancer and in vitro depletion of Tregs by ADCC using anti-human CCR4 mAb (KM2760).
2. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, Fukuda M, Uenaka A, Oka M, and Nakayama E. Clinical effect of XAGE1 (GAGED2a) antigen expression and antibody response in EGFR mutated and wild-type advanced lung adenocarcinoma.

＜European Respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014＞

Kobashi Y, Ikeda M, Mouri K, Kato S, Oka M. Clinical evaluation of MIGRAs (IP-10 and MIG) including two IGRAs (QFT and T-SPOT) for the diagnosis of tuberculosis infection.

＜European Academy of Allergy and Clinical Immunology Congress 2014, Copenhagen, Denmark, June 7-11, 2014＞

Katoh S, Ikeda M, Shimizu H, Obase Y, Hirashima M, Oka M. Preventive effect of galectin-9 on double-stranded RNA-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced murine asthma

＜21st Annual Cancer Research Institute International Cancer Immunotherapy Symposium, New York, USA, Sep 30-Oct 2, 2013＞

1. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Isobe M, Uenaka A, Fukuda M, Oka M, Nakayama E. Prolonged overall survival in XAGE-1b(GAGED2a) antibody positive NSCLC patients.
2. Kurose K, Ohue Y, Mizote Y, Isobe M, Uenaka A, Oka M, Nakayama E. Depletion of Tregs from PBMCs by treatment with defucosylated anti-CCR4 mAb.

＜ERS Annual Congress, Barcelona, Spain, September 7-11, 2013＞

1. Kobashi Y, Mouri K, Obase Y, Kato S, Oka M. Clinical analysisof patients with pulmonary nontuberculous mycobacterial disease complicated with pneumothorax.
2. Kobashi Y, Mouri K, Obase Y, Kato S, Oka M. Clinical evaluation of glycopeptidolipid core antigen IgA antibodies for serodiagnosis of mycobacterium avium complex pulmonary disease.

＜European Academy of Allergy and Clinical Immunology Congress, Milan, Italy, June22-26, 2013＞

Katoh S, Oomizu S, Niki T, Shimizu H Obase Y, Korenaga M, Hirashima M, Oka M. Possible regulatory role of galectin-9 on Ascaris summ-induced eosinophilic lung inflammation in mice.

＜104nd Annual Meeting of American Association of Cancer Research (AACR), Washington, USA, April6-10, 2013＞

1. Ohue Y, Kurose K, Eikawa S, Mizote Y, Matsumoto H, Isobe M, Uenaka A, Fukuda M, Nakayama E, Oka M. Immune response to XAGE-1b (GAGED2a) in NSCLC patients and its clinical relevance
2. Kurose K, Eikawa S, Mizote Y, Ohue Y, Isobe M, Uenaka A, Oka M, Nakayama E. Depletion of Tregs from PBMCs by treatment with defucosylated anti-CCR4 mAb

＜20th annual international cancer immunotherapy symposium, New York, USA, Oct1-3, 2012＞

1. Ohue Y, Eikawa S, Mizote Y, Matsumoto H, Isobe M, Uenaka A, Oka M, Nakayama E. Immune response to XAGE-1b(GAGED2a)in NSCLC patients and its clinical relevance
2. Kurose K, Eikawa S, Mizote Y, Ohue Y, Isobe M, Uenaka A, Oka M, Nakayama E. Treg depletion from PBMCs by treatment with defucosylated anti-human CCR4 mAb.

＜Annual Congress of European Respiratory Society, Vienna, Austria, September 1-5, 2012＞

1. Kobashi Y, Ikeda M, Mouri K, Obase Y, Oka M. Clinical evaluation of GPL core IgA antibodies for serodiagnosis of MAC pulmonary disease
2. Obase Y, Shimoda T, Oka M, Kishikawa R, Iwanaga T. Cough variant asthma may be a incipience of bronchial asthma.
3. Ikeda M, Kobashi Y, Mouri K, Obase Y, Oka M. Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan.

＜European Academy of Allergy and Clinical Immunology Congress, Geneva, Switzerland, June16-20, 2012＞

Katoh S, Kaminuma O, Shimizu H, Obase Y, Oka M. CD44 is critical for airway accumulation of Th2 cells induced by antigen challenge in mice.

＜103rd Annual Meeting of American Association of Cancer Research (AACR), Chicago, IL, USA, March 31- April 4, 2012＞

1. Ohue Y, Eikawa S, Mizote Y, Matsumoto H, Okazaki N, Isobe M, Uenaka A, Nakayama E, Oka M. Correlation of antibody and T-cell responses against XAGE-1b in NSCLC patients
2. Matsumoto H, Ohue Y, Eikawa S, Mizote Y, Kurose K, Isobe M, Uenaka A, Nagayasu T, Oka M, Nakayama E. Immunogenicity of cancer/testis antigen XAGE-1d in patients with non-small-cell lung cancer (NSCLC)

＜19th Annual International Cancer Immunotherapy Symposium, New York, USA, October 3-5 , 2011＞

1. Ohue Y, Eikawa S, Mizote Y, Matsumoto H, Okazaki N, Isobe M, Uenaka A, Oka M and Nakayama E Correlation of antibody and T-cell responses against XAGE-1b in NSCLC patients.
2. Eikawa S, Kakimi K, Isobe M, Kuzushima K, Ohue Y, Ikeuchi K, Uenaka A, Udono H, Lloyd Old, Oka M and Nakayama E. Induction of CD8 T Cell Responses Restricted to Multiple HLA Class I Alleles in a Cancer Patient by Immunization with a 20-Mer NY-DSO-1 91-110) Peptide.

＜Annual Congress of European Respiratory Society, Amsterdam, the Netherlands, September 24-27, 2011>

1. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Transitional change of the relationship between clinical efficacy of treatment for pulmonary MAC disease and drug-sensitivity test for MAC isolated.
2. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Comparative study of the usefulness of TST and three interferon-gamma release assays (IGRAs) for the differential diagnosis of pulmonary tuberculosis.

＜30th Congress of the European Academy of Allergy and Clinical Immunology, Istanbul, Turkey, June11-15, 2011＞

Katoh S, Matsumoto N, Shimizu H, Obase Y, Fukushima K, Hirashima M, Oka M. Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia.

＜102nd Annual Meeting of American Association of Cancer Research (AACR), Orlando, FL, USA, April 2-6, 2011＞

1. Ohue Y, Eikawa S, Matsumoto H, Mizote Y, Isobe M, Uenaka A, Fukuda M, Nakayama E, Oka M. XAGE-1b (GAGED2a) immunity in non-small-cell lung cancer
2. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E. Enrichment of Foxp3+ CD4 Tregs in migrated T-cells to IL-6-and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6

＜47th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, IL, USA, June 3-7, 2011＞

Ogawara D, Fukuda M, Nakamura Y, Ueno S, Suyama N, Nakatomi K, Iida T, Kanda T, Oka M, Kohno S. Fever during cancer chemotherapy: analysis of 1,016 chemotherapy cycles.

＜14th World Conference on Lung Cancer (IASLC), Amsterdam, The Netherlands, July 3-7, 2011＞

Ikeda T, Yamaguchi H, Doi S, Nakatomi K, Nakamura Y, Nagashima S, Takatani H, Fukuda M, Soda H, Oka M, Kohno S. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.

＜67th Annual Meeting of American Academy of Allergy Asthma & Immunology, San Francisco, CA, USA, March 18-22, 2011＞

Shimoda T, Obase Y, Imaoka M, Kishikawa R, Iwanaga T. Evaluation of central and peripheral airways and analysis of airway inflammation by impulse oscillometry in bronchial asthma patients.

＜18th Annual International Cancer Immunotherapy Symposium, New York, NY, USA, October 6-8 , 2010＞

1. Eikawa S, Ohue Y, Isobe M, Ikeuchi K, Uenaka A, Kakimi K, Oka M and Nakayama E. CD8 T-Cell response in NY-ESO-1 F-peptide vaccinated patients.
2. Ohue Y, Eikawa S, Mizote Y, Matsumoto H, Okazaki N, Isobe M, Uenaka A, Oka M, Nakayama E. Spontaneous XAGE-1b immunity in patients with non-small-cell lung cancer.

＜European Respiratory Society, Barcelona, Spain, September 18-22, 2010＞

1. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Clinical evaluation of two interferon-gamma release assay (IGRA) tests for immunocompromised patients.
2. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Comparative study of therapeutic effects of combined chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease.
3. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M, for the Chugoku-Shikoku mycobacterial committee. Desenstitization therapy for allergic reactions to antituberculous drugs.

＜14th International Congress of Immunology, Kobe, Japan, August 25-27, 2010＞

1. Eikawa S^*, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E. Enrichment of Foxp3⁺ CD4 Tregs in migrated T-cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. (^*Young Investigator Award)
2. Ohue Y, Eikawa S, Mizote Y, Okazaki N, Isobe M, Fukuda M, Uenaka A, Oka M, Nakayama E. XAGE-1b immunity in patients with non-small-cell lung cancer.

＜29th Congress of the European Academy of Allergy and Clinical Immunology, London, England, June 5-9, 2010＞

Katoh S, Maeda S, Fukuoka H, Wada T, Moriya S, Yamaguchi K, Uchida Y, Miyagi T. A crucial role of sialidase Neu1 in hyaluronan receptor function of CD44 in Th2-mediated airway inflammation of murine acute asthmatic model.

＜101st Annual Meeting, Washington DC, USA, April 17-21, 2010＞

1. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E. Enrichment of Tregs in migrated T-cells to IL-6- and IL-8-expressing tumors through induction of CXCR1 by IL-6.
2. Ohue Y, Eikawa S, Mizote Y, Okazaki N, Isobe M, Uenaka A, Fukuda M, Nakayama E, Oka M. Spontaneous immune responses against XAGE-1b in patients with non-small cell lung cancer (NSCLC).

＜35th ESMO Congress, Milan, Italy, October 8-10, 2010＞

Kinoshita A, Fukuda M, Nakamura Y, Soejima Y, Nakatomi K, Doi S, Fukuda M, Soda H, Oka M, Kohno S. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited -disease small-cell lung cancer.

＜12th International Symposium on Human Chlamydial Infections, Salzburg, Austria, June 20-25, 2010＞

Kawai Y, Tabuchi M, Yanatori I, Yasui Y, Miura K, Miyashita N, Ouchi K, Kishi F. Genome-wide screening of pathogen effectors in Chlamydophila pneumoniae using a yeast expression system.

＜13th World Conference on Lung Cancer, San Francisco, USA, July 31-August 4, 2009＞

Takemoto S, Nagashima S, Soda H, Fukuda Mi, Nakamura Y, Iida T, Nakatomi K, Kasai T, Takatani H, Fukuda Ma, Kinoshita A, Soejima Y, Oka M, Kohno S. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer.

＜European Respiratory Society, Vienna, Austria, September 12-16, 2009＞

1. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment.
2. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Comparison of T-cell interferon-γ release assay to Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis.
3. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for patients with active tuberculosis disease stratified by age groups.
4. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test in patients with nontuberculous mycobacterial disease.

＜Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009＞

Kasai T, Fukuda Mi, Nakamura Y, Nakatomi K, Iida T, Fukuda Ma, Kinoshita A, Soda H, Oka M, Kohno S. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer.

＜American Coference of Chest Physician Annual Meeting, San Diego, USA, October31-November 5, 2009＞

1. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Oka M, and the Atypical Pathogen Study Group. Macrolide-resistant Mycoplasma pneumoniae in patients with community-acquired pneumonia in Japan.
2. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Oka M, and the Atypical Pathogen Study Group. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing.

＜14th Congress of the APSR and 3rd Joint Congress of the APSR/ACCP, Seoul, Korea, November 14-18, 2009＞

1. Abe Y, Fukuda Mi, Nakamura Y, Nakatomi K, Iida T, Fukuda Ma, Kinoshita A, Soda H, Oka M, Kohno S. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer.
2. Ogawara D, Fukuda M, Ueno S, Hisatomi K, Futsuki Y, Nakatomi K, Iida T, Nakamura Y, Oka M, Kohno S. Fever during cancer chemotherapy: analysis of 718 chemotherapy cycles.

＜American Academy of Allergy Asthma & Immunology, Annual meeting, Philadelphia, Pennsylvania, March 14-18, 2008＞

Shimoda T, Imaoka M, Kishikawa R, Shoji S, Nishima S, Obase Y, Miyatake A, Kasayama S. Usefulness of High-Sensitivity C-Reactive Protein as a Marker of Airway Inflammation in Cough-Variant and Bronchial Asthma.

＜44th Annual Meeting for American Society of Clinical Oncology (ASCO), Chicago, Illinois, USA, May 30-June 3, 2008＞

Fukuda M, Nakamura Y, Kasai T, Kinoshita A, Fukuda M, Motoshima K, Iida T, Nakatomi K, Soda H, Oka M, Kohno S. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer.

＜6th Meeting of the European Society for Chlamydia Research, Aarhus, Denmark, July 1-4, 2008＞

1. Miyashita N, Ouchi K, Kishi F, Tabuchi M, Kawai Y, Oda K, Kawasaki K, Oka M. Rapid diagnosis of Chlamydia pneumoiae pneumonia by using an immunochromatographic test for the detection of immunoglobulin M antibodies.
2. Oda K, Okazaki A, Kawai Y, Miyashita N, Kishi F, Tabuchi M, Kishimoto T, Yamazaki T, Ouchi K, Matsumoto A. Plaque formation of Chlamydophila pneumoniae.

＜33rd Annual Meeting for European Society of Medical Oncology (ESMO), Stockholm, Sweden, September 12-16, 2008＞

Doi S, Nakamura Y, Fukuda M, Takatani H, Fukuda M, Kinoshita A, Soda H, Oka M, Tsukamoto K, Kohno S. UGT1A1*6 and UGT1A1*27 are associated with irinotecan-induced severe neutropenia in Japanese patients with NSCLC.

＜EHRLICH II, 2nd World Conference on Magic Bullets, Nürnberg, Germany, October 3-5, 2008＞

Fukuda M, Nakamura Y, Nakatomi K, Fukuda Ma, Kinoshita A, Soda H, Oka M, Tsukamoto K, Masuda N, Kohno S. UGT1A1*6 and UGT1A1*27 are associated with irinotecan-induced severe neutropenia in Japanese patients with NSCLC: results of a randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine.

＜European Respiratory Society, Annual Congress, Berlin, Germany, October 4-8, 2008＞

1. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis.
2. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice.
3. Kobashi Y, Mouri K, Obase Y, Miyashita N, Oka M. Clinical utility of T-cell-based assay for the diagnosis of extrapulmonary tuberculosis.
4. Imaoka M, Shimoda T, Kishikawa R, Shoji S, Nishima S, Obase Y. Anti-inflammatory effect of budesonide on the central and peripheral airway inflammation in cough-variant and mild bronchial asthma.
5. Obase Y, Shimizu H, Sugiu T, Ohfuji T, Ohue Y, Miyashita N, Kobashi Y, Oka M. Asthma control test (ACT) problem and the complementary effect by peak flow rate (PEFR) measurement at outpatient department.

＜48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, Oct 25-28,2008＞

Kawai Y, Yamaguchi T, Oda K, Miyashita N, Tabuchi M, Kishi F, Ouchi K. High prevalence of macrolide - resistant mycoplasma pneumonia infection in Japan.

＜43rd Annual Meeting of American Society of Clinical Oncology, Chicago, USA, June 2007＞

Fukuda M, Soda H, Nakamura Y, Fukuda Ma, Kinoshita A, Nagashima S, Nakano H, Yamaguchi H, Kohno S, Oka M. Phase II trial of irinotecan plus cisplatin with concurrent thoracic radiotherapy (TRT) in patients with previously untreated locally advanced non-small cell lung cancer (NSCLC) （肺がん）

＜17th Annual Congress of the European Respiratory Society, Stockholm, Sweden, September 2007＞

1. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis （感染症）
2. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Comparison of the tuberculin skin test and two commercial blood tests for diagnosing active mycobacterium tubedrculosis infection and nontuberculous mycobacterium infection（感染症）
3. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Clinical evaluation of QuantuFERON TB-2G test for immunocompromised patients（感染症）

＜14th European Cancer Conference (ECCO), Barcelona, Spain, September 2007＞

Kinoshita A, Fukuda Mi, Nagashima S, Fukuda Ma, Takatani H, Nakano H, Nakamura Y, Oka M, Soda H, Kohno S. Randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine in untreated advanced non-small cell lung cancer （肺がん）

＜12th World Conference on Lung Cancer, Seoul, Korea, September 2007＞

1. Iida T, Nakamura Y, Fukuda M, Takatani H, Nagashima S, Kinoshita A, Fukuda Mi, Soda H, Oka M, Kohno S. Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC) （肺がん）

＜12th Congress of the Asian Pacific Society of Respirology/2nd Joint Congress of the APSR/ACCP, Gold Coast, Australia, December 2007＞

1. Miyashita N, Ouchi K, Kawasaki K, Kawai Y, Tsumura N, Bannai H, Iwata S, Oka M. Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydia pneumonia （感染症）
2. Miyashita N, Obase Y, Kobashi Y, Sshimizu H, Sugiu T, Ohue Y, Yagi S, Mouri K, Ouchi K, Oka M. Clinical features of severe Mycoplasma pneumonia in adults admitted to an intensive care unit（感染症）

1. Kobashi Y, Shouji H, Yagi S, Mouri K, Obase Y, Fukuda M, Yoshida K, Miyashita N, Fujii M, Oka M. Usefulness of a dsiagnostic method of tuberculosis infection, QuantiFERON TB-2G, in a contact investigation of medical staffs. Annual Meeting for European Respiratory Society (Munchen, Germany), 2006
2. Kobashi Y, Shouji H, Yagi S, Mouri K, Obase Y, Fukuda M, Yoshida K, Miyashita N, Mikio Oka. Clinical evaluation of a diagnostic method of tuberculosis infection, QuantiFERON TB-2G, for active tuberculosis and nontuberculous mycobacteriosis. Annual Meeting for European Respiratory Society (Munchen, Germany), 2006
3. Kobashi Y, Shouji H, Yagi S, Mouri K, Obase Y, Fukuda M, Yoshida K, Miyashita N, Matsushima T, Oka M. A double blind randamized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease. Annual Meeting for European Respiratory Society (Munchen, Germany), 2006
4. Miyashita N, Obase Y, Fukuda M, Shoji H, Ouchi K, Ishida T, Nakahama C, Oka M. Japanese guidelines for the management of community-acquired pneumonia: clinical differentiation of atypical pneumonia. 11th International Symposium on Human Chlamydial Infections (Ontario, Canada), 2006
5. Nakamura Y, Sano K, Fukuda M, Takatani H, Nagashima S, Kinoshita A, Fukuda M, Soda H, Oka M, Kohno S. Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer. 42nd Annual Meeting for American Society of Clinical Oncology (Atlanta, GA, USA), 2006